<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Anteris Technologies Global Corp. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/anteris-technologies-global-corp-common-stock</link>
<description>Latest news and press releases for Anteris Technologies Global Corp. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 10:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/anteris-technologies-global-corp-common-stock" rel="self" type="application/rss+xml" />
<item>
<title>Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial</title>
<link>https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-technologies-secures-cms-reimbursement-supporting-us-site-activation-for-paradigm-trial</link>
<guid isPermaLink="true">https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-technologies-secures-cms-reimbursement-supporting-us-site-activation-for-paradigm-trial</guid>
<pubDate>Tue, 28 Apr 2026 10:00:00 GMT</pubDate>
<description>MINNEAPOLIS and BRISBANE, Australia, April 28, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced it has secured U.S. Medicare reimbursement eligibility for the global pivotal PARADIGM Trial under a Centers for Medicare & Medicaid Services (CMS) national coverage poli</description>
</item>
<item>
<title>Anteris Reports 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-reports-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-reports-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>MINNEAPOLIS and BRISBANE, Australia, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR),</description>
</item>
<item>
<title>Anteris to Present at Healthcare Investor Conferences TD Cowen and Barclays</title>
<link>https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-to-present-at-healthcare-investor-conferences-td-cowen-and-barclays</link>
<guid isPermaLink="true">https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-to-present-at-healthcare-investor-conferences-td-cowen-and-barclays</guid>
<pubDate>Mon, 23 Feb 2026 11:30:00 GMT</pubDate>
<description>MINNEAPOLIS and BRISBANE, Australia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, is pleased to advise that Vice Chairman and Chief Executive Officer, Wayne Paterson will be presenting at both the TD Cowen 46th Annual Healthcare Conference and the Barclays 28th Annual H</description>
</item>
<item>
<title>Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises</title>
<link>https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-announces-strategic-investment-medtronic-210200913</link>
<guid isPermaLink="true">https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-announces-strategic-investment-medtronic-210200913</guid>
<pubDate>Thu, 22 Jan 2026 21:02:00 GMT</pubDate>
<description>MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced today it has completed a $90 million strategic investment from Medtronic, plc (Galway, Ireland) (NASDAQ: MDT) (Medtronic), the world’s largest medical technology company. The investm</description>
</item>
<item>
<title>Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock</title>
<link>https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-technologies-global-corp-announces-210100173</link>
<guid isPermaLink="true">https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-technologies-global-corp-announces-210100173</guid>
<pubDate>Thu, 22 Jan 2026 21:01:00 GMT</pubDate>
<description>MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the closing of its underwritten public offering (the “Offering”) of 40,000,000 shares of its common stock, including the exercise in full of the underwriters’ option to pu</description>
</item>
<item>
<title>Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering</title>
<link>https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-technologies-global-corp-announces-035300992</link>
<guid isPermaLink="true">https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-technologies-global-corp-announces-035300992</guid>
<pubDate>Wed, 21 Jan 2026 03:53:00 GMT</pubDate>
<description>MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the pricing of its public offering (the “Offering”) of 34,782,609 shares of its common stock (the “Shares”). The Shares are being sold at a public offering price of $5.75</description>
</item>
<item>
<title>Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic</title>
<link>https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-technologies-global-corp-announces-210100730</link>
<guid isPermaLink="true">https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-technologies-global-corp-announces-210100730</guid>
<pubDate>Tue, 20 Jan 2026 21:01:00 GMT</pubDate>
<description>MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that it is offering to sell, subject to market and other conditions, $200 million of shares of its common stock through a proposed underwritten public offering (the “Offer</description>
</item>
<item>
<title>Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves</title>
<link>https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-technologies-presents-data-100-110000135</link>
<guid isPermaLink="true">https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-technologies-presents-data-100-110000135</guid>
<pubDate>Mon, 17 Nov 2025 11:00:00 GMT</pubDate>
<description>MINNEAPOLIS and BRISBANE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) today released 30-day clinical outcomes for the DurAVR® THV in one hundred severe aortic stenosis patients with small aortic annuli (aortic annulus area 404 ± 37mm2). The DurAVR® THV demonstrated single digit mean gradients, large effective orifice areas (EOAs), no moderate or severe paravalvular leaks and no valve related mortality, with 97% f</description>
</item>
<item>
<title>Anteris Announces Results for the Third Quarter of 2025</title>
<link>https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-announces-results-third-quarter-225200437</link>
<guid isPermaLink="true">https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-announces-results-third-quarter-225200437</guid>
<pubDate>Wed, 12 Nov 2025 22:52:00 GMT</pubDate>
<description>MINNEAPOLIS, Minn. and BRISBANE, Australia , Nov. 12, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended September 30, 2025, and provided a corporate update. Third Quarter 2025 Highlights Continued FDA engagement during the Quarter to</description>
</item>
<item>
<title>FDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)</title>
<link>https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/fda-approves-anteris-duravr-thv-120000781</link>
<guid isPermaLink="true">https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/fda-approves-anteris-duravr-thv-120000781</guid>
<pubDate>Mon, 03 Nov 2025 12:00:00 GMT</pubDate>
<description>PARADIGM: A Prospective rAndomized tRial Assessing the safety and effectiveness of the DurAVR® bIomimetic valve designed for physioloGic flow compared to CoMmercial TAVR devices MINNEAPOLIS and BRISBANE, Australia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Anteris announced today it has received U.S. Food and Drug Administration (FDA) approval to initiate PARADIGM, its global Investigational Device Exemption (IDE) clinical trial which is designed to evaluate the DurAVR® Transcatheter Heart Valve (THV) i</description>
</item>
<item>
<title>Anteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year</title>
<link>https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-duravr-thv-demonstrates-favorable-220800782</link>
<guid isPermaLink="true">https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-duravr-thv-demonstrates-favorable-220800782</guid>
<pubDate>Tue, 28 Oct 2025 22:08:00 GMT</pubDate>
<description>MINNEAPOLIS and BRISBANE, Australia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced one-year clinical outcomes for the DurAVR® Transcatheter Heart Valve (THV) in symptomatic severe aortic stenosis patients with small aortic annuli (aortic annulus area 396 + 37 mm2).</description>
</item>
<item>
<title>Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)</title>
<link>https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-technologies-announces-first-patients-214300080</link>
<guid isPermaLink="true">https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-technologies-announces-first-patients-214300080</guid>
<pubDate>Mon, 27 Oct 2025 21:43:00 GMT</pubDate>
<description>MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the first patients have been enrolled and successfully treated in the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial for patients with severe calci</description>
</item>
<item>
<title>Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025</title>
<link>https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-technologies-announces-one-clinical-124300305</link>
<guid isPermaLink="true">https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-technologies-announces-one-clinical-124300305</guid>
<pubDate>Mon, 27 Oct 2025 12:43:00 GMT</pubDate>
<description>MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that one-year clinical outcomes with the DurAVR® Transcatheter Heart Valve (THV) will be presented by Rishi Puri MD PhD, at TCT® 2025 – The 37th Annual Transcatheter Cardiovas</description>
</item>
<item>
<title>Anteris Receives First European Regulatory Clearance to Commence DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)</title>
<link>https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-receives-first-european-regulatory-131800616</link>
<guid isPermaLink="true">https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-receives-first-european-regulatory-131800616</guid>
<pubDate>Wed, 15 Oct 2025 13:18:00 GMT</pubDate>
<description>MINNEAPOLIS and BRISBANE, Australia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced today it has received regulatory clearance from the Danish Medicines Agency to initiate the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial in patients with severe calci</description>
</item>
<item>
<title>Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders</title>
<link>https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-technologies-global-corp-announces-063000181</link>
<guid isPermaLink="true">https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-technologies-global-corp-announces-063000181</guid>
<pubDate>Fri, 19 Sep 2025 06:30:00 GMT</pubDate>
<description>MINNEAPOLIS and BRISBANE, Australia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that after convening its Special Meeting of Stockholders (the “Special Meeting”) virtually on Thursday, September 18, 2025, at 5:00 p.m. Central time (being 8:00 a.m. AEST on</description>
</item>
<item>
<title>Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders</title>
<link>https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-technologies-global-corp-announces-125000618</link>
<guid isPermaLink="true">https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-technologies-global-corp-announces-125000618</guid>
<pubDate>Thu, 11 Sep 2025 12:50:00 GMT</pubDate>
<description>MINNEAPOLIS and BRISBANE, Australia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that its Special Meeting of Stockholders (the “Special Meeting”), which was originally scheduled to be held on Thursday, September 11, 2025, at 5:00 p.m. Central time (being</description>
</item>
<item>
<title>Anteris Announces Results for the Second Quarter of 2025</title>
<link>https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-announces-results-second-quarter-205200899</link>
<guid isPermaLink="true">https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-announces-results-second-quarter-205200899</guid>
<pubDate>Mon, 11 Aug 2025 20:52:00 GMT</pubDate>
<description>MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercialising cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended June 30, 2025, and provided a corporate update. Second Quarter 2025 Highlights 130 patients implanted with the DurAVR® THV since the star</description>
</item>
<item>
<title>Anteris Appoints David Roberts and Gregory Moss to its Board of Directors</title>
<link>https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-appoints-david-roberts-gregory-025200978</link>
<guid isPermaLink="true">https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-appoints-david-roberts-gregory-025200978</guid>
<pubDate>Tue, 10 Jun 2025 02:52:00 GMT</pubDate>
<description>New Directors Bring Extensive NASDAQ Expertise Across Legal, Operational and Corporate Leadership CapacitiesMINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Bo</description>
</item>
<item>
<title>Anteris Announces Results for the First Quarter of 2025</title>
<link>https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-announces-results-first-quarter-214500556</link>
<guid isPermaLink="true">https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-announces-results-first-quarter-214500556</guid>
<pubDate>Tue, 13 May 2025 21:45:00 GMT</pubDate>
<description>MINNEAPOLIS and BRISBANE, Australia, May 13, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended March 31, 2025, and provided a corporate update. First Quarter 2025 Highlights Investigational Device Exemption (“IDE”) for the DurAVR® TH</description>
</item>
<item>
<title>Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV</title>
<link>https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-technologies-reaches-clinical-milestone-111500161</link>
<guid isPermaLink="true">https://6ix.com/company/anteris-technologies-global-corp-common-stock/news/anteris-technologies-reaches-clinical-milestone-111500161</guid>
<pubDate>Mon, 31 Mar 2025 11:15:00 GMT</pubDate>
<description>MINNEAPOLIS and BRISBANE, Australia, March 31, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris® or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices, announces a significant milestone in our mission to restore heart valve patients to healthy function. Our first in class, biomimetic DurAVR® Transcatheter Heart Valve (THV) has now been used to treat over 100 patients worldw</description>
</item>
</channel>
</rss>